Nanomix Corporation

Equities

NNMX

US63008H2013

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 13:25:08 2023-12-29 EST			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-.--%

2023	Nanomix Corporation Announces Chief Executive Officer Changes	CI
2023	Nanomix Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI

Alan M. Hoberman Resigns as Director of Boston Therapeutics, Inc

November 15, 2016 at 05:11 pm

On November 14, 2016, Alan M. Hoberman, Ph.D. provided Boston Therapeutics, Inc. with a letter of resignation dated September 15, 2016, pursuant to which Mr. Hoberman resigned as a director of the Company.

Latest news about Nanomix Corporation

Nanomix Corporation Announces Chief Executive Officer Changes	11-24	CI
Nanomix Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-07	CI
Nanomix Corporation Auditor Raises 'Going Concern' Doubt	23-04-06	CI
Nanomix Corporation Appoints Christopher R. Hetterly as Chief Financial Officer	23-01-25	CI
Nanomix Corporation Enters into Distribution Agreement for the eLab System with Gepa Srl in Italy	22-11-29	CI
Nanomix Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Nanomix Corporation Enters into an Exclusive Veterinary Distribution Agreement for the eLab System with Woodley Equipment Company, Ltd	22-11-09	CI
Nanomix Corporation announced that it has received $0.069779 million in funding from Woodley Equipment Company Ltd.	22-11-08	CI
Nanomix Corporation Enters into Multi-Country Distribution Agreement for the Elab System with Mast Group Limited	22-11-04	CI
Nanomix Corporation Announces Distribution Agreement with Diaclinic SpA	22-10-20	CI
Nanomix Enters into Distribution Agreement for the Elab System and Future New Products with Ips Genomix S.A.L. in the Middle East	22-09-12	CI
Nanomix Corporation Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies	22-09-02	CI
Nanomix Names Tadd S. Lazarus to Board of Directors	22-08-31	CI
Nanomix Corporation Appoints Tadd S. Lazarus to its Board of Directors as Independent Director	22-08-31	CI
Nanomix Enters into Distribution Agreement for the Elab System and Future New Products with Bioasia Pte Ltd in Singapore	22-08-23	CI
Nanomix Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Nanomix Corporation Appoints Thomas Schlumpberger as Member of the Board of Directors	22-07-26	CI
Nanomix Corporation Announces Executive Changes	22-07-26	CI
Nanomix Corporation Announces Distribution Agreement for the eLab System with Biotron Ltd. in Israel	22-07-21	CI
Nanomix Corporation Initiates New Clinical Study for the eLab S1 Panel	22-06-22	CI
Nanomix Corporation Receives IVDR Certification for the eLab Analyzer	22-06-14	CI
Nanomix Granted Ce Mark for Elab S1 Assay Panel for Whole Blood Samples	22-05-26	CI
Nanomix Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-17	CI
Nanomix Corporation Auditor Raises 'Going Concern' Doubt	22-04-11	CI
Nanomix Corporation Announces the Relocation of its Corporate Headquarters	22-03-30	CI

Chart Nanomix Corporation

Duration

Period

More charts

Company Profile

Nanomix Corporation is engaged in development of mobile point-of-care diagnostics. The Company operates through its Nanomix eLab System platform and assays that provide quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The platform is designed to provide rapid test results in a handheld device at the first point of patient contact in locations that range from emergency departments to long term and assisted care facilities, to urgent care and emergency medical response settings. Its platform is performed in a range of in vitro diagnostic assays, such as electrochemical immunoassay and enzymatic assays. Its eLab System utilizes a nano-biosensor with multiple detection electrodes to generate multiple electrochemical assay results. Its S1 Assay panel is used as an aid in diagnosing infections, such as sepsis. Its CRP test results can be used to evaluate infection, tissue injury, and inflammatory disorders.

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement Evolution

More financial data

Sector Medical Software & Technology Services

	1st Jan change	Capi.
NANOMIX CORPORATION	-.--%	4.9K
VEEVA SYSTEMS INC.	-9.49%	28.16B
PRO MEDICUS LIMITED	+25.35%	8.33B
SECTRA AB	+33.25%	4.39B
EVOLENT HEALTH, INC.	-35.85%	2.43B
VERADIGM INC.	-9.44%	1.6B
OMNICELL, INC.	-13.39%	1.5B
LUNIT INC.	-32.84%	1.15B
SIMULATIONS PLUS, INC.	+7.80%	964M
B-SOFT CO.,LTD.	-37.56%	872M

Medical Software & Technology Services